Home/Filings/4/0001181431-10-031733
4//SEC Filing

GLEESON CHRISTOPHER M 4

Accession 0001181431-10-031733

CIK 0001487371other

Filed

Jun 6, 8:00 PM ET

Accepted

Jun 7, 5:14 PM ET

Size

18.1 KB

Accession

0001181431-10-031733

Insider Transaction Report

Form 4
Period: 2010-06-03
GLEESON CHRISTOPHER M
Director10% Owner
Transactions
  • Other

    Stock Option (Right to Buy)

    2010-06-03+25,08025,080 total
    Exercise: $6.49Exp: 2019-12-22Common Stock (25,080 underlying)
  • Other

    Common Stock

    2010-06-03+229,232229,232 total(indirect: By Trust)
  • Purchase

    Common Stock

    2010-06-03$6.00/sh+1,333,333$7,999,9981,562,565 total(indirect: By Trust)
  • Other

    Stock Option (Right to Buy)

    2010-06-03+25,08025,080 total
    Exercise: $6.93Exp: 2019-09-24Common Stock (25,080 underlying)
  • Other

    Warrant

    2010-06-03+88,31788,317 total
    Exercise: $9.98From: 2010-06-03Common Stock (88,317 underlying)
  • Other

    Common Stock

    2010-06-03+31,18531,185 total
  • Other

    Stock Option (Right to Buy)

    2010-06-03+4,8214,821 total
    Exercise: $6.49From: 2010-06-03Exp: 2019-12-22Common Stock (4,821 underlying)
Footnotes (7)
  • [F1]Received in exchange for ordinary shares of Osmetech plc in connection with the reorganization of GenMark Diagnostics, Inc. The reorganization resulted in GenMark becoming the parent company of Osmetech, GenMark's parent company prior to the reorganization, through a scheme of arrangement under Part 26 of the U.K. Companies Act of 2006, but did not alter the proportionate interests of security holders. The number of shares issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 ordinary shares of Osmetech for one share of GenMark common stock.
  • [F2]Mr. Gleeson is the trustee of the Gleeson Family Trust and may be deemed to have beneficial ownership of this securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
  • [F3]Received in exchange for options to purchase ordinary shares of Osmetech plc. The number of options issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 options to purchase ordinary shares of Osmetech for an option to purchase one share of GenMark common stock.
  • [F4]33% of the option shares vest and become exercisable on January 20, 2010, January 20, 2011 and January 20, 2012 respectively.
  • [F5]11,494 of the option shares have vested and became exercisable and the remaining option shares vest and become exercisable in 26 monthly installments beginning on June 23, 2009.
  • [F6]Received in exchange for warrants to purchase ordinary shares of Osmetech plc. The number of warrants issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 warrants to purchase ordinary shares of Osmetech for a warrant to purchase one share of GenMark common stock.
  • [F7]The warrant expires on the earlier of (i) 60 days after Mr. Gleeson is no longer a director of the Issuer and (ii) June 30, 2012.

Documents

1 file

Issuer

GenMark Diagnostics, Inc.

CIK 0001487371

Entity typeother

Related Parties

1
  • filerCIK 0001134540

Filing Metadata

Form type
4
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 5:14 PM ET
Size
18.1 KB